PeerVoice is an independent, professional medical publishing concern focused on gathering and reporting information pertaining to clinically relevant advances and developments in the science and practice of medicine. As publishers of PeerVoice Publications, PeerVoice is solely responsible for the selection of publication topics, the preparation of editorial content and the distribution of all materials it publishes.
http://www.peervoice.com
Wong Seng Weng, MBBS, MRCP, FAMS - Treatment Approaches in EGFR-Mutant NSCLC Post-TKI and Chemotherapy: What Now and What Next?
Visit https://www.peervoice.com/FQC860 to view the entire programme with slides. After completing “Wong Seng Weng, MBBS, MRCP, FAMS - Treatment Approaches in EGFR-Mutant NSCLC Post-TKI and Chemotherapy: What Now and What Next?”, participants will be able to: Recognise current unmet needs for patients with EGFR-mutant NSCLC who progress after multiple lines of therapy; Assess the clinical relevance of available safety and efficacy data evaluating novel therapies in patients with EGFR-mutant NSCLC who have progressed following TKI therapy and chemotherapy; and Identify evidence-based best practices for managing patients with EGFR-mutant NSCLC who have progressed following TKI therapy and chemotherapy.